Growth and Spread of Breast Cancer Linked to Tumor Cells' Expression of a Cartilage Protein
|
By LabMedica International staff writers Posted on 27 Apr 2016 |

Image: High expression of COMP in breast cancer cells, seen here in brown, was associated with poor clinical prognosis for the patient. Cancer cells expressing COMP became more invasive and changed their metabolism, which allowed them to survive better and spread to other organs (Photo courtesy of Dr. Anna Blom, Lund University).
A team of Swedish cancer researchers has identified a protein in breast tumors and surrounding stromal tissue that contributes to the development and spread of the disease.
Investigators at Lund University (Malmö, Sweden) using tissue microarrays derived from two cohorts of patients with breast cancer found that the protein COMP (cartilage oligomeric matrix protein), a soluble pentameric protein expressed in cartilage and involved in collagen organization, was expressed to a varying degree in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Normal breast tissue did not express detectable levels of COMP.
The investigators injected MDA-MB-231breast cancer cells that stably expressed COMP into the mammary fat pads of SCID (CB-17/Icr-Prkdcscid/Rj) mice. They reported in the April 11, 2016, online edition of the journal Oncogene that tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control tumors that did not express the protein.
In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of the enzyme matrix metalloprotease-9. Microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. Furthermore, in vitro measurement of cell respiration indicated that COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect, in which they produced energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.
Based on these results, the investigators concluded that COMP was a novel biomarker in breast cancer, which contributed to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.
"We saw a clear association between high levels of COMP and a worse breast cancer prognosis. With more research, COMP has the potential of becoming an indicator of aggressive breast cancer, and thereby providing early and valuable information before deciding on an appropriate treatment," said senior author Dr. Anna Blom, professor of protein chemistry at Lund University.
Related Links:
Lund University
Investigators at Lund University (Malmö, Sweden) using tissue microarrays derived from two cohorts of patients with breast cancer found that the protein COMP (cartilage oligomeric matrix protein), a soluble pentameric protein expressed in cartilage and involved in collagen organization, was expressed to a varying degree in the tumor cells and surrounding stroma. High levels of COMP in tumor cells correlated, independently of other variables, with poor survival and decreased recurrence-free survival. Normal breast tissue did not express detectable levels of COMP.
The investigators injected MDA-MB-231breast cancer cells that stably expressed COMP into the mammary fat pads of SCID (CB-17/Icr-Prkdcscid/Rj) mice. They reported in the April 11, 2016, online edition of the journal Oncogene that tumors expressing COMP were significantly larger and were more prone to metastasize as compared with control tumors that did not express the protein.
In vitro experiments confirmed that COMP-expressing cells had a more invasive phenotype, which could in part be attributed to an upregulation of the enzyme matrix metalloprotease-9. Microarray analyses of gene expression in tumors formed in vivo showed that COMP expression induced higher expression of genes protecting against endoplasmic reticulum stress. Furthermore, in vitro measurement of cell respiration indicated that COMP-expressing cells appeared to undergo a metabolic switch, that is, a Warburg effect, in which they produced energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.
Based on these results, the investigators concluded that COMP was a novel biomarker in breast cancer, which contributed to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.
"We saw a clear association between high levels of COMP and a worse breast cancer prognosis. With more research, COMP has the potential of becoming an indicator of aggressive breast cancer, and thereby providing early and valuable information before deciding on an appropriate treatment," said senior author Dr. Anna Blom, professor of protein chemistry at Lund University.
Related Links:
Lund University
Latest BioResearch News
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
Channels
Clinical Chemistry
view channel
Blood Test Detects Testicular Cancer Missed by Standard Markers
Testicular cancer most often affects adolescents and young adults and is highly treatable when found early. Diagnosis can be difficult when tumors do not produce sufficient levels of standard blood-based... Read more
Routine Blood Tests Identify Biomarkers Linked to PTSD
Post-traumatic stress disorder (PTSD) is associated with a range of chronic physical health conditions and affects multiple organ systems. Clinical laboratories routinely measure blood analytes that reflect... Read moreMolecular Diagnostics
view channel
CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
Respiratory virus co-circulation complicates differential diagnosis, as overlapping symptoms can obscure etiology. Multiplex testing typically depends on multiple enzymes or fluorophores and multistep... Read more
Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
Early-stage invasive breast cancer is frequently managed with breast-conserving surgery followed by adjuvant radiation therapy, but the magnitude of benefit from radiation varies among patients.... Read more
Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
Despite decades of effective drug regimens, tuberculosis remains the leading cause of death from an infectious disease, driven in part by limited access to accurate, rapid testing. Conventional diagnostics... Read more
Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more







